By Joey Wong, Investor Research Analyst, LSN
Digital RESI September is off to a great start, but we’re not slowing down! We will be hosting a second week of live investor panels. Check out next week’s lineup, and register here for RESI September 2020 to participate in these live panels!
All panels at Digital RESI September are live-streamed. There will be two live panel sessions each day through the end of the conference, September 8-16. We welcome all Digital RESI September attendees to join and participate in these live sessions. Registered attendees can RSVP via the partnering platform to receive the dial-in information to join. For those who cannot make the live sessions, all the panel videos will be available via the virtual agenda.
Digital RESI September registrants will hear from the leading industry experts about their investment strategies and differentiated approaches, recent investments and areas of interest, and much more.
Below is the schedule for next week’s live panel sessions:
|
Diagnostics Investors Panel – New Generation of Technologies Changing Treatment Paradigms Monday, September 14, 10:00 – 10:50 am EST
|
|
Big Pharma Panel – Pipeline Strategy for Preclinical and Early Clinical Assets Monday, September 14, 2:00 – 2:50 pm EST
|
|
Medical Device Investors Panel – Investing in Novel Engineering Tuesday, September 15, 10:00 – 10:50 am EST
|
|
Early Stage Therapeutics Investors Panel – Bringing the Newest Therapies to the Clinic Tuesday, September 15, 2:00 – 2:50 pm EST
|
|
Family Offices & Angel Investors Panel – The Search for New Approaches to Diagnosing & Treating Caner Wednesday, September 16, 10:00 – 10:50 am EST
|
|
Digital Health Investors Panel – Leveraging Software to Lower Costs and Improve the Quality of Care Wednesday, September 16, 2:00 – 2:50 pm EST
|
Judy is a veteran in the investment world with 15+ years of both public and private equities experience. Coupled with years of global marketing experience, Judy is energetic and widely regarded as a growth catalyst with contagious passion. Judy currently serves as Onelin Capital Principal & General Manager, overseeing the entire family office’s operation as well as fund investments.
Dr. Weiyong Sun is currently Senior Director, Searching and Evaluation, Global Business Development at Daiichi Sankyo Group. He joined Daiichi Sankyo Japan in April 2002. He was involved in a broad range of R&D activities from target discovery to clinical development of a number of anti-diabetes drugs. In October 2007, Dr. Sun was elected to be assigned to work for Daiichi Sankyo Research Institute in the U.S. He was responsible for identifying and evaluating in-licensing, partnering and research collaboration opportunities. His current focus is in Immunology Cardio-Renal, Ophthalmology and Rare Disease. Dr. Sun received an M.D. from Beijing Medical University (now Peking University Medical School), a Ph.D. in Biochemistry from the University of Tokyo and an MBA from Columbia Business School. He was a postdoctoral fellow in the Blood Research Institute, Medical College of Wisconsin.
Yao Ho is a Senior Director of Business Development at LYFE Capital. Previously, he was a part of Yangtze River Pharmaceutical Group, where he was a BD Manager. At Yangtze River Pharmaceutical Group, he was part of a team that would help the parent organization source, evaluate, coordinate due diligence and negotiate with potential international partners for pharmaceuticals, biologics and medical devices. Yao has also worked at various diagnostics, nanotechnology and digital health startups where he started as an R&D Engineer and was a member of the founding team at other companies. Yao is an MBA graduate from Tsinghua University in partnership with MIT and Bachelor’s in Biomedical Engineering from UC-Irvine with a specialization in bio-photonics and research in microfluidics.
Haolin Sung is the founder and the managing partner at Chaperone Investment, a Taiwan based VC fund focusing on angel and early stage investment in healthcare and biotech sector. He has 10+ years of experience in this field and serves as a board director for several companies including Panlabs, MountainVet, and was the board director at Pharmigene. Mr. Sung also serves in critical roles at several of the Chaperone portfolio companies including Celtech and Caliway to assist these companies in funding and business development/ licensing activities. Prior to Chaperone Investment, Mr. Sung was the director of the direct investment department for Diamond Biofund, the largest Biotech VC in Taiwan and the deputy director of Microbio Biotech Shanghai. He also worked for First Capital Management as a healthcare/biotech industry analyst. Mr. Sung earned his EMBA at Columbia University and London business school and has a B.S. in Biochemistry from Dong Hwa University.
Currently on an expatriate assignment from Japan, Haru Sugino is leading the global scouting activities for Otsuka Pharmaceutical Co., Ltd working closely with Otsuka’s US and EU BD affiliates. Haru is a part of Otsuka’s evaluation and negotiation team, charged with identifying, evaluating, and negotiating transactions to in-license new innovative compounds that address unmet medical needs in CNS/neuro and renal diseases for both global development or for regional development in Japan and Asia. Haru has been with Otsuka for 22 years in various roles, including sales, pre-clinical drug discovery, clinical R&D, commercial, and business development. Haru has a PhD for neuropharmacology, and moved to business development in 2016 after successfully launching a drug in US on which he worked for 10 years from pre-clinical discovery through to commercialization.
Next Phase Newsletter 